977 related articles for article (PubMed ID: 12529666)
41. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
[TBL] [Abstract][Full Text] [Related]
42. Interferon augments PML and PML/RAR alpha expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans retinoic acid to induce maturation of a retinoid-resistant promyelocytic cell line.
Nason-Burchenal K; Gandini D; Botto M; Allopenna J; Seale JR; Cross NC; Goldman JM; Dmitrovsky E; Pandolfi PP
Blood; 1996 Nov; 88(10):3926-36. PubMed ID: 8916959
[TBL] [Abstract][Full Text] [Related]
43. WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential.
Laurenzana A; Cellai C; Vannucchi AM; Pancrazzi A; Romanelli MN; Paoletti F
Leukemia; 2005 Mar; 19(3):390-5. PubMed ID: 15674364
[TBL] [Abstract][Full Text] [Related]
44. RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells.
Gianni M; Fratelli M; Bolis M; Kurosaki M; Zanetti A; Paroni G; Rambaldi A; Borleri G; Rochette-Egly C; Terao M; Garattini E
Oncotarget; 2017 Jun; 8(23):37041-37060. PubMed ID: 27419624
[TBL] [Abstract][Full Text] [Related]
45. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
46. Targeting of PML/RARalpha is lethal to retinoic acid-resistant promyelocytic leukemia cells.
Nason-Burchenal K; Allopenna J; Bègue A; Stéhelin D; Dmitrovsky E; Martin P
Blood; 1998 Sep; 92(5):1758-67. PubMed ID: 9716606
[TBL] [Abstract][Full Text] [Related]
47. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation.
Shao W; Benedetti L; Lamph WW; Nervi C; Miller WH
Blood; 1997 Jun; 89(12):4282-9. PubMed ID: 9192750
[TBL] [Abstract][Full Text] [Related]
48. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
[TBL] [Abstract][Full Text] [Related]
49. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells.
Duprez E; Lillehaug JR; Gaub MP; Lanotte M
Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786
[TBL] [Abstract][Full Text] [Related]
50. A network including PU.1, Vav1 and miR-142-3p sustains ATRA-induced differentiation of acute promyelocytic leukemia cells - a short report.
Grassilli S; Nika E; Lambertini E; Brugnoli F; Piva R; Capitani S; Bertagnolo V
Cell Oncol (Dordr); 2016 Oct; 39(5):483-489. PubMed ID: 27480083
[TBL] [Abstract][Full Text] [Related]
51. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells.
Benedetti L; Levin AA; Scicchitano BM; Grignani F; Allenby G; Diverio D; Lo Coco F; Avvisati G; Ruthardt M; Adamo S; Pelicci PG; Nervi C
Blood; 1997 Aug; 90(3):1175-85. PubMed ID: 9242550
[TBL] [Abstract][Full Text] [Related]
52. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint.
Biondi A; Luciano A; Bassan R; Mininni D; Specchia G; Lanzi E; Castagna S; Cantù-Rajnoldi A; Liso V; Masera G
Leukemia; 1995 Sep; 9(9):1461-6. PubMed ID: 7658712
[TBL] [Abstract][Full Text] [Related]
53. Poor response to all-trans retinoic acid therapy in a t(11;17) PLZF/RAR alpha patient.
Guidez F; Huang W; Tong JH; Dubois C; Balitrand N; Waxman S; Michaux JL; Martiat P; Degos L; Chen Z
Leukemia; 1994 Feb; 8(2):312-7. PubMed ID: 8309256
[TBL] [Abstract][Full Text] [Related]
54. All-trans retinoic acid potentiates megakaryocyte colony formation: in vitro and in vivo effects after administration to acute promyelocytic leukemia patients.
Visani G; Zauli G; Tosi P; Ottaviani E; Gibellini D; Manfroi S; Celeghini C; Pagliarini C; Bassini A; Tura S
Leukemia; 1994 Dec; 8(12):2183-7. PubMed ID: 7528859
[TBL] [Abstract][Full Text] [Related]
55. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha.
Rego EM; Ruggero D; Tribioli C; Cattoretti G; Kogan S; Redner RL; Pandolfi PP
Oncogene; 2006 Mar; 25(13):1974-9. PubMed ID: 16331271
[TBL] [Abstract][Full Text] [Related]
56. The acute promyelocytic leukemia-specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cells.
Rogaia D; Grignani F; Grignani F; Nicoletti I; Pelicci PG
Leukemia; 1995 Sep; 9(9):1467-72. PubMed ID: 7658713
[TBL] [Abstract][Full Text] [Related]
57. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
[TBL] [Abstract][Full Text] [Related]
58. cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha.
Duprez E; Lillehaug JR; Naoe T; Lanotte M
Oncogene; 1996 Jun; 12(11):2451-9. PubMed ID: 8649787
[TBL] [Abstract][Full Text] [Related]
59. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho).
Fukutani H; Naoe T; Ohno R; Yoshida H; Miyawaki S; Shimazaki C; Miyake T; Nakayama Y; Kobayashi H; Goto S
Leukemia; 1995 Sep; 9(9):1478-82. PubMed ID: 7658715
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of semiquantitative reverse transcriptase-polymerase chain reaction assay of PML/retinoic acid receptor alpha mRNA and in vitro differentiation assay as prognostic prediction in acute promyelocytic leukemia treated with all-trans retinoic acid.
Iwakiri R; Inokuchi K; Dan K; Wakabayashi I
Nihon Ika Daigaku Zasshi; 1996 Aug; 63(4):259-67. PubMed ID: 8810554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
